Trial Profile

A Phase I/Ib Trial of Trotabresib (BMS-986378), an Oral BET Inhibitor) in Combination With Vinorelbine and Radiation Therapy in HER2+ Breast Cancer Patients With Central Nervous System Metastasis and Leptomeningeal Disease (CA076-1008)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 04 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trotabresib (Primary) ; Vinorelbine (Primary)
Indications Brain metastases; Cancer metastases; HER2 positive breast cancer; Meningeal carcinomatosis
Focus Adverse reactions

28 Mar 2024 Planned End Date changed from 31 Dec 2031 to 27 Mar 2024.
28 Mar 2024 Planned primary completion date changed from 31 Dec 2029 to 27 Mar 2024.
28 Mar 2024 Planned initiation date changed from 31 Dec 2024 to 31 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com